Thera-SAbDab

ALIROCUMAB

>   Structural Summary
TherapeuticAlirocumab
TargetPCSK9
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGFTFNNYAMNWVRQAPGKGLDWVSTISGSGGTTNYADSVKGRFIISRDSSKHTLYLQMNSLRAEDTAVYYCAKDSNWGNFDLWGRGTLVTVSS
Light ChainDIVMTQSPDSLAVSLGERATINCKSSQSVLYRSNNRNFLGWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTTPYTFGQGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyVelocImmune Mouse
INN Year Proposed2012
INN Year Recommended2013
Companies InvolvedRegeneron Pharmaceuticals, Sanofi, University Hospital Inselspital
Conditions ApprovedHypercholesterolaemia, Hyperlipoproteinaemia type IIa, Atherosclerosis
Conditions ActiveCoronary artery disease
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]